BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2024 2:49:02 AM | Browse: 111 | Download: 468
 |
Received |
|
2023-12-20 02:19 |
|
Peer-Review Started |
|
2023-12-20 02:19 |
|
First Decision by Editorial Office Director |
|
2024-01-31 06:37 |
|
Return for Revision |
|
2024-01-31 15:19 |
|
Revised |
|
2024-02-20 04:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-07 01:11 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-07 02:26 |
|
Articles in Press |
|
2024-04-07 02:26 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-14 12:36 |
|
Publish the Manuscript Online |
|
2024-06-15 02:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tian-Qi An, Hui Qiu, Quan-Bo Zhou, Hong Zong, Shuang Hu, Yu-Gui Lian and Rui-Hua Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rui-Hua Zhao, PhD, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Road, Zhengzhou 450000, Henan Province, China. zrh_ly@163.com |
| Key Words |
Colorectal cancer; Fruquintinib; Regorafenib; Programmed death-1 inhibitor; Real-world |
| Core Tip |
Fruquintinib (F) and regorafenib (R) monotherapy or in combination with programmed death-1 (PD-1) inhibitors, are commonly used treatment options for microsatellite stable or proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC). Nowadays, there is limited research data comparing the efficacy of F plus PD-1 inhibitors (FP) and R plus PD-1 inhibitors (RP) to F and R monotherapy. And there is also no consensus on whether combination therapy is more effective than monotherapy. We included a total of 313 patients with MSS/pMMR metastatic CRC (mCRC) who received at least third-line treatment with F, R, FP, or RP at our hospital, and then conducted statistical analysis on their clinical data and prognosis. And then found that the FP regimen has the potential to yield favorable survival benefits for MSS/pMMR mCRC, making it worthy of further research and investigation. |
| Publish Date |
2024-06-15 02:49 |
| Citation |
An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol 2024; 16(6): 2449-2462 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i6/2449.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i6.2449 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
